Résumé
The authors have retracted this article (Xiao et al., 2018). After publication, they became aware that a number of studies included in the meta-analysis did not meet the eligibility criteria and that errors were made in classification and statistical analysis. The conclusions presented are therefore unreliable. All authors agree with this retraction.
Résumé
<p><b>OBJECTIVE</b>To discuss the clinical characteristics of remnant gastric cancer (RGC).</p><p><b>METHODS</b>Clinical data of 163 patients with RGC admitted to our department from January 2005 to January 2015 were collected and reviewed.</p><p><b>RESULTS</b>The time duration of all the RGC patients between primary gastrectomy and occurrence of RGC ranged from 9 to 46 years (median 27.5 years). Among 163 patients, 112(68.7%) patients manifested as discomfort in the upper abdominal region, 47(28.8%) patients had hematemesis and melena, 38(23.3%) had vomiting, 17(10.4%) had swallowing difficulty and 12 (7.4%) had decreased weights. In pathology, 127 (77.9%) cases were median or low grade adenocarcinoma; 114(69.8%) patients were Borrmann type III( gastric cancer under endoscope; 145 (88.9%) patients were TNM III(-IIII( gastric cancer. A total of 106 patients underwent operation, including 75(70.8%) patients of radical resection and 31(29.3%) patients of palliative resection. Patients mainly received Billroth II( anastomosis (77.4%) as digestive tract reconstruction, while 57 cases did not receive surgical operation. The overall 1-, 3-, and 5-year survival rates of the patients were 76.1%, 43.4%, 25.8% respectively. The median survival time of patients receiving radical resection and those receiving palliative resection was 34.6 months and 16.4 months respectively, whereas patients who did not receive surgical operation died 3-8 months after initial diagnosis.</p><p><b>CONCLUSIONS</b>Regular gastroscopy is necessary for patients undergoing gastrectomy for over 10 years. Radical resection is of great importance in the treatment of remnant gastric cancer.</p>
Sujets)
Adolescent , Adulte , Enfant , Humains , Adulte d'âge moyen , Jeune adulte , Adénocarcinome , Troubles de la déglutition , Gastrectomie , Moignon gastrique , Gastroentérostomie , Gastroscopie , , Tumeurs de l'estomacRésumé
Gastrointestinal carcinomas, whose incidence increases in recent years, are among the malignancies with highest morbidity and mortality. Many patients are always advanced stages when having diagnosis. So far, there are no any reliable tumor biomarkers which are able to screen people with high risk of developing cancer. Studies have shown that the expression level of Lgr4 is high in gastrointestinal carcinomas and Lgr4 is useful in diagnosis, differential diagnosis and prognosis judgment of these carcinomas. Lgr4 belongs to the G-protein-coupled receptors family. Its function is to potentiate Wnt signaling and plays an important role in the development of multiple organs. Recent studies find that Lgr4 has close relationship with the development of many gastrointestinal carcinomas, such as gastric cancer and colorectal cancer(CRC). In this article we review recent progress in understanding the relationship between Lgr4 and gastrointestinal carcinomas.
Résumé
Expressions of interleukin-6 (IL-6) and its receptor (gp80、gp130) in 8 patients with Graves' disease (GD) were compared with those in 8 euthyroid patients with nodular goiter or benign thyroid adenoma. The thyroid tissues of GD expressed significantly higher IL-6 mRNA, gp130 mRNA and IL-6 protein than those of the control group, suggesting that activated IL-6/gp130 signal pathway in the thyroid tissue may contribute to the pathogenesis of GD.
Résumé
Objective To investigate the relationship between Homocysteine (Hcy) and incipient diabetic nephropathy in type 2 diabetes mellitus (DM).Methods The plasma Hcy level was measured by high performance liquid chromatography with fluorescence detection in 67 patients with type 2 DM and 47 control persons,the plasma thrombomodulin(sTM),folate and vitamin B 12 were determined simultaneously.Results The plasma Hcy level was higher in type 2 DM patients than that in control subjects (15.27?6.04?mol/L vs 12.10?1.86?mol/L, P